



PledPharma's 2018 annual report published

Stockholm, April 8, 2019. PledPharma AB today announces that the Annual Report for 2018 now is available at the company's website, www.pledpharma.se. A printed version can be ordered through info@pledpharma.se or +468 -679 72 10.

For further information, please contact:

Yilmaz Mahshid, CFO

Tel. +46-(0)72 231 68 00

yilmaz.mahshid@pledpharma.se

About PledPharma

PledPharma is an innovative, unique and integrated pharmaceutical drug development company, focusing on improving treatments for diseases with substantial unmet medical need. The company's most advanced project PledOx[®] is being developed to reduce nerve damage associated with chemotherapy. A global phase III program is ongoing. The drug candidate Aladote[®] is being developed to reduce the risk of acute liver injury associated with acetaminophen poisoning. A proof of principle study has been successfully completed and will serve as the basis for the continued development. PledPharma (STO: PLED) is listed on Nasdaq First North. Erik Penser Bank is the company's Certified Adviser (tel +46 8 463 83 00, certifiedadviser@penser.se). For more information, see <http://www.pledpharma.com/>